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Abstract Cancer survivors often relapse due to evolving
drug-resistant clones and repopulating tumor stem cells.
Our preclinical study demonstrated that terminal cancer
patient’s lymphocytes can be converted from tolerant
bystanders in vivo into effective cytotoxic T-lymphocytes
in vitro killing patient’s own tumor cells containing drug-
resistant clones and tumor stem cells. We designed a
clinical trial combining peginterferon a-2b with imatinib
for treatment of stage III/IV gastrointestinal stromal tumor
(GIST) with the rational that peginterferon a-2b serves as
danger signals to promote antitumor immunity while
imatinib’s effective tumor killing undermines tumor-
induced tolerance and supply tumor-speciﬁc antigens in
vivo without leukopenia, thus allowing for proper dendritic
cell and cytotoxic T-lymphocyte differentiation toward
Th1 response. Interim analysis of eight patients demon-
strated signiﬁcant induction of IFN-c-producing-CD8
?,
-CD4
?, -NK cell, and IFN-c-producing-tumor-inﬁltrating-
lymphocytes, signifying signiﬁcant Th1 response and NK
cell activation. After a median follow-up of 3.6 years,
complete response (CR) ? partial response (PR) = 100%,
overall survival = 100%, one patient died of unrelated
illness while in remission, six of seven evaluable patients
are either in continuing PR/CR (5 patients) or have pro-
gression-free survival (PFS, 1 patient) exceeding the
upper limit of the 95% conﬁdence level of the genotype-
speciﬁc-PFS of the phase III imatinib-monotherapy
(CALGB150105/SWOGS0033), demonstrating highly
promising clinical outcomes. The current trial is closed in
preparation for a larger future trial. We conclude that
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DOI 10.1007/s00262-011-1185-1combination of targeted therapy and immunotherapy is safe
and induced signiﬁcant Th1 response and NK cell activa-
tion and demonstrated highly promising clinical efﬁcacy in
GIST, thus warranting development in other tumor types.
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Introduction
Despite effective treatments achieving remission, cancer
survivors often relapse, after which interventions become
largely unsuccessful. One culprit is drug-resistant clones—
pre-existing and evolving continuously—and another is
tumor stem cells—repopulating, resilient, and poorly
understood. With their unique features, once outgrowth has
occurred, both culprits can evade standard therapies and
prevail. The innate and adaptive immunity have been
shown to play important roles in protecting the host
through tumor immunosurveillance [1–6]. Unfortunately,
mechanisms of tumor-induced tolerance enable tumors to
escape immunosurveillance [7]. However, the delicate
balance can be restored if we can design novel treatment
that can break tolerance while promote innate and adaptive
antitumor immunity.
Dendritic cells (DCs) capture, process, and cross-present
antigens in the context of MHC class-I and costimulatory
molecules to subsets of T-lymphocytes, and play critical
roles in the regulation and development of distinct immune
responses [8–10] including (1) Th1 adaptive cell-mediated
immunity (Th1 response) signiﬁed by interferon-c (IFN-c)
secretion and play major roles in protection against
pathogens and tumors [1–6], (2) Th2, (3) Th17, and (4)
T-regulatory responses (tolerance).
IFN-a is a type-1 IFN and a physiological danger signal
[11,12]canupregulateexpressionofMHCclass-Imolecules
and costimulatory molecules on DCs, activate innate
immunity, modulate DCs, promote Th1 response, help clo-
nal expansion/survival and memory differentiation of
T-lymphocytes[9–13],andhasbeenshowntobeaneffective
vaccine adjuvant in animal models [14] and clinical trials
[15, 16]. The immunological consequences of tumor cell
death induced by individual chemotherapy agents [17] and
the subsequent differentiation of DCs and T-lymphocytes in
the ensuing 2-week span are of pivotal importance in inﬂu-
encing the development toward the distinct immune
responses (Th1, Th2, Th17, or tolerance). Cytotoxic che-
motherapy often results in prolonged severe leukopenia
depriving DCs of proper maturation (differentiation), thus
often resulting in a tolerant/dysfunctional immune state.
With recognition of the IFN-a qualities [9–14], the
pivotal role of DCs in the development of distinct immune
responses [8–10] and support from our preclinical data, we
hypothesize that (1) combining IFN-a with effective non-
marrow-suppressive antitumor agent(s) could induce innate
immunity and Th1 response; (2) the antitumor immunity
can help eradicating tumor cells including the drug-resis-
tant clones and tumor stem cells upfront thus improve
response rate; (3) most importantly, antitumor immunity
can monitor continuously and eradicate the various
continuing-evolving drug-resistant clones and the resilient
tumor stem cells when they ﬁrst emerge at the cellular/
subclinical level prior to outgrowth, and this would delay/
prevent relapse, ultimately leading to the improvements in
progression-free survival (PFS) and overall survival (OS).
To test the hypothesis, we designed a new strategy
aiming at developing innate immunity and Th1 response
concomitant with partial response (PR) or complete
response (CR) achieved by effective non-marrow-
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123suppressive drug therapy. Gastrointestinal stromal tumor
(GIST), a sarcoma with incidence of 5000/year in US,
represents an excellent model to test our hypothesis for the
following reasons. First, imatinib mesylate (IM, Gleevec
,
Glivec
)[ 18], a selective inhibitor of ABL, KIT, PDGFRA
B, is highly effective, induces swift apoptosis/necrosis of
GIST within 3–7 days [19], andisnon-marrow-suppressive,
allowing proper DC and cytotoxic T-lymphocyte differen-
tiation toward Th1 response. Second, GIST cell alterations
include cancer/testis antigens [20], tumor-antigens created
by activating mutations in KIT (c-kit)o rPDGFRA [21–24]
and new mutation(s) responsible for IM resistance [25–27].
Third,IM-monotherapytrialsinGISTpatientshavereported
response rates (PR ? CR) of 54% [28], 52% [29, 30], and
48% [22, 30]. The median PFS remains B 2 years [22, 29,
30]mainlyduetothedevelopmentofIMresistance[25–27].
Discontinuing IM resulted in high rate of relapse due to
repopulating stem cells [31]. Thus,better therapiesforGIST
are needed.
IM was reported to induce DC-mediated natural killer
(NK) cell IFN-c production [32, 33] and potentiate adaptive
immunity through IM-off-target inhibition of KIT on DCs
[34] and inhibition of Ido [35]; both IM-off-target immuno-
logical anti-GIST effects plus IM-inhibition of KIT/PDG
FRA signaling contribute to the IM-monotherapy efﬁcacy
[22, 28–30] as described above and is less than satisfactory.
We intend to bring out the full potential of anti-GIST
immunity by a new strategy of combining peginterferon a-2b
(PegIFNa2b, Peg-Intron
)[ 36] with IM and have demon-
strated signiﬁcant Th1 response, innate immunity, and highly
promising clinical outcome comparing to IM-monotherapy
[22], strongly support all three parts of our hypothesis.
Materials and methods
Preclinical study
Specimens were collected under MD Anderson Institu-
tional Review Board (IRB) protocols LAB_00143. Primary
tumor cells were isolated after digesting fresh tumor with
collagenase. The chimeric SYN-SSX was sequenced [37].
Peripheral blood mononuclear cell (PBMC)-derived DCs
were isolated by plastic adherence and culture supple-
mented with GM-CSF and IL-4. Cytokine cocktail con-
sisted of TNF-a (R&D), IL-1b (R&D), IL-6 (R&D), and
PGE-2 (Sigma) [38]. IL-12-p70 was analyzed using ELISA
(Biosources, Camarillo, CA.) and read with UV-900
microplate reader (Bio-Tek Instruments, Winooski, VT).
The plastic non-adherent cells were used to positively
select CD8
? T-lymphocytes using anti-CD8 monoclonal
antibody (mAb) coupled to magnetic microbeads (Miltenyi
Biotec, Auburn, CA).
IFN-c-enzyme-linked immunosorbent spot
(IFN-c-ELISPOT) assay
CD8
? T-lymphocytes were cultured in AIM-V medium
supplemented with IL-2 and IL-7 and stimulated with vari-
ous antigen preparations twice, total 14 days, to generate
CTLs. The 96-well ELISPOT plate (Millipore, Billerica,
MA) was precoated with anti-IFN-c antibody, incubated at
4C overnight, plated with CD8
? T-lymphocytes at
2 9 10
5 cells/well, and stimulated with 4 9 10
4 irradiated
primary tumor cells for 40 h at 37C. Biotinylated IFN-c
antibody was added, followed by streptavidin peroxidase.
IFN-c spots were counted using an ELISPOT reader.
51Cr-release assay
Cryopreserved primary tumor cells were used as targets
and K562 cells as control. We labeled 2 9 10
6 target cells
with 100 lCi of Na2
51CrO4 (ICN Biomedicals, Irvine, CA)
and distributed 3,000 target cells in each well. Blocking
experiments were performed using anti-HLA-A.B.C anti-
body and isotype control (Dako, Carpinteria, CA).
Clinical trial
Refer to ‘‘Results’’.
Genotyping
As described previously [23].
IFN-c-ﬂow cytometry
PBMCs were cultured with phorbol ester PMA (5 ng/ml)
plus ionomycin (745 ng/ml) for 1 h, add brefeldin A (5
mcg/ml) and cultured for additional 4 h. After surface
staining with CD4-PerCP, CD8-APC, or CD3-FITC (BD
Biosciences), cells were ﬁxed and stained with anti-human
IFN-c-PE (BioLegend, San Diego, CA) [39]. Data were
acquiredonaFACSCaliburﬂowcytometer(BDBiosciences)
and analyzedwithFlowJosoftware(TreeStarInc.,Ashland).
Immunohistochemical analysis and confocal
microscopy
Antigen retrieval with preheated EDTA/Tris buffer pH 9.0
for CD8, CD56, and CD4; and citrate Buffer pH 6.0 for
IFN-c, FasL, and granzyme B. Antibodies included CD4,
CD8, CD56 (Dako, Carpinteria, CA); IFN-c (Abcam,
Cambridge, MA); and FasL and granzyme B (Novus Bio-
logicals, Littleton, CO), goat anti-rabbit IgG antibody
conjugated with Texas Red, and goat anti-mouse IgG
conjugated with Alexa Fluor 488 (Novus Biologicals).
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123Images were acquired using Fluo View software on an
Olympus FV1000 confocal laser scanning microscope.
Results
Pre-clinical study
Cancer patient’s anergic T-lymphocytes in vivo can be
converted into effective cytotoxic T-lymphocytes capable
of killing patient’s own primary tumor cells in vitro
A stage III synovial sarcoma patient (HLA-A24/A29)
received standard neoadjuvant chemotherapy (doxorubicin
and ifosfamide), achieved PR, and underwent surgery to
achieve disease-free status. The patient later relapsed with
wild spread metastasis and rapid progression failing all
systematic treatment; leukapheresis was performed to col-
lect PBMC. At the time of surgery, the post-neoadjuvant
chemotherapy residual tumor consisting of resilient tumor
stem cells and chemotherapy-resistant cells—as evidenced
by clinical relapse and metastasis shortly after surgery
along with drug resistance—were cryopreserved to serve as
targets for in vitro cytotoxic T-lymphocytes (CTL) analysis
as opposed to using cell lines as targets [37]. Two tumor-
speciﬁc-9-mer-peptides encompassing the joining of SYT-
SSX1 (Peptides #1 and 2) (Fig. 1a) exhibit high predicted
binding afﬁnity [40] with HLA-A24 class 1 molecule
Fig. 1 CTLs targeted at
patient’s own tumor cells.
a Chimeric SYT-SSX1 in a
HLA-A24/A29 synovial
sarcoma. b Predicted binding of
two tumor-speciﬁc-9-mer-
peptides with HLA class-I
molecules. c IL-12-p70
secretion by mature autologous
DCs. d IFN-c–ELISPOT assay.
e
51Cr-release assay. CTLs that
were generated by stimulation
with antigen preparations III1,
III2, III1?2,I V 1,I V 2,I V 1?2 can
induce signiﬁcant primary
tumor cell lysis using IFN-c-
ELISPOT (P\0.01) and
51Cr-
release assay (P\0.05). The
speciﬁc lysis of primary tumor
cells can be abrogated by
neutralizing antibody against
HLA-A.B.C loci and at 4C( e,
right panel)
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123(Fig. 1b). DCs that were matured with a cytokine cocktail
(TNF-a,I L - 1 b,I L - 6 ,a n dP G E - 2 )[ 38] showed signiﬁcant
secretion of IL-12–p70 (P\0.01, Fig. 1c). Autologous
PBMC-derived CD8
? T-lymphocytes were stimulated with
four antigen preparations (Fig. 1d, I–IV) twice in vitro to
generate CTLs. When antigen-speciﬁc peptides #1 & 2 were
presented by mature DCs, we demonstrated signiﬁcant
cytotoxicity against primary tumor cells by both IFN-c–
ELISPOT (P\0.01, Fig. 1d ,I I I&I V )a n d
51Cr release
assays (P\0.05, Fig. 1e, III & IV). The percent tumor-
speciﬁc lysis exhibited a dose-dependent relationship with
effector-to-target ratio.
51Cr release was completely blocked
by neutralizing anti-HLA-A.B.C antibody and cold temper-
ature at 4C( F i g .1e, right panel) indicating the essential role
of the HLA class-I molecules and speciﬁcity of tumor lysis.
To the best of our knowledge, this is the ﬁrst report
using a patient’s own post-chemotherapy residual drug-
resistant primary tumor cells—a source of micrometastasis
and recurrence—as targets for CTL assays and provided
direct and convincing evidence that a terminal cancer
patient’s T-lymphocytes can be converted from tolerant
bystanders ignoring the tumor growth in vivo into tumor-
speciﬁc effective CTLs in vitro (Fig. 1d, e). Our preclinical
studies served two purposes. First, these encouraging
results help to justify immunotherapy approach to over-
come relapse especially when no other treatment option is
in sight due to current poor understanding of the culprits
causing relapse. Second, our preclinical study methods are
readily applicable for testing the development of tumor-
speciﬁc immunity during clinical trial by collecting PBMC
and applying
51Cr release or IFN-c–ELOSPOT assays
using primary tumor cells (if available) as CTL targets.
Without further dwelling on in vitro studies, we move
toward our ultimate goal of restoring/stimulating antitumor
immunity in vivo in cancer patients.
Aiming at developing antitumor immunity in parallel
with achieving PR/CR by drug therapy, we initiated a new
strategy of combining PegIFNa2b (3rd signal/danger
signal) with IM (killing tumor cells to undermine tumor-
induced tolerance and provide 1st and 2nd signals—antigen
and co-stimulation) in GIST to test our hypothesis.
Clinical study
GIST clinical trial design is summarized in Fig. 2
Combination treatment of PegIFNa2b plus IM-induced
signiﬁcant IFN-c-producing-lymphocytes IFN-c serves
Abbreviations:  PBMC, peripheral blood monocytes; IM, imatinib; PegIFNa2b, peginterferon α-2b; HD,
high-dose; LD, low-dose; wk, week.
*Eligibility:  Stages III gastrointestinal stromal tumor (GIST) patients with primary tumor >6 cm or stage
IV (metastatic) GIST of any size.
†End points:  Clinical endpoints include safety, response rate (complete response + partial response), time
to response, progression-free survival and overall survival. Laboratory end points include NK cell 
activation, and Th1 immune response.
‡Combination treatment:  For KIT exon 11 mutation GIST, starts IM at 400 mg/day, and for KIT exon 9 
mutation GIST, starts IM at 800 mg/day and allow dose reduction as needed. PegIFNa2b dosage and 
schedule are shown in above schema. If absolute neutrophil count is <1.5 x109/L or platelets is <100 
x109/L, PegIFNa2b dose will be on hold until bone marrow recovers.
¶Specimens:  PBMC were collected by leukapheresis before starting IM and within a week before the last 
LD-PegIFNa2b. In between the two leukapheresis, PBMC were collected at specific time points using CPT 
Cell Preparation Tube (BD, Franklin Lakes, NJ 07417). 
§Response evaluation:  (i) RECIST, (ii) PET-CT criteria [41], and (iii) Choi criteria [42, 43]. 
**Comparison/control:  We used IM-monotherapy CALGB150105/SWOGS0033 phase III Study results
(746 patients enrolled, 382 genotyped) for comparison, it reported objective response rates and median PFS 
respectively for KIT exon 11 mutation GIST as 72% and 741 days, for KIT exon 9 mutation as 44% and 
501 days, and for WT GIST as 45% and 384 days [22]
††Status:  This phase II clinical trial was approved by The University of Utah IRB (IRB_00022172) and 
registered with ClinicalTrials.gov (NCT00585221). Informed consent was obtained before enrollment. It 
was opened in May 2007, and closed for accrual by PI in July 2009 due to highly promising results and our 
intension to incorporate the insight gained in the interim analysis into a larger future trial. 
If progression, get off
clinical trial and pursue
standard care including
the option of re-initiation
of PegIFNa2b
Day 0: start HD-PegIFNa2b 
(3 mcg/kg/wk) X 4, followed 
by maintenance LD-
PegIFNa2b (1.5 mcg/kg/wk) 
X18 
–(3–5) days: start IM, 
continue until progression
Pre-treatment leukapheresis to
collect PBMC
4-6 weeks after the last
LD-PegIFNa2b  
contemplate surgery  to 
render patients disease-
free
Leukapheresis at 1-7
days before the last LD-
PegIFNa2b
Fig. 2 Clinical trial design
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123critical function in innate, and adaptive cell-mediate
immunity [2–6] is tightly regulated and produced pre-
dominantly by four cell types only, activated NK, NKT
cells, Th1 CD4
?, and Th1 CD8
? CTLs [6] and is the
signature of Th1 response. Five of the eight patients
enrolled consented to donate PBMC. Total IFN-c-produc-
ing-lymphocytes and subgroups of IFN-c-producing
-CD8
?, -CD4
?, and -CD4
-CD8
--lymphocyte (most likely
NK cells) were barely detectable before treatment (Fig. 3a,
black columns), and they increased signiﬁcantly to
18 ± 1.3% (P\0.0004), 32 ± 4.8% (P\0.003), 15 ±
2.5% (P\0.006), and 7.3 ± 0.3% (P\0.0001), respec-
tively (Fig. 3a, red columns) after four HD-PegIFNa2b
(3 mcg/kg/week) with continuing IM. IFN-c–production of
individual patients at single cell level by ﬂow cytometry is
shown in Fig. 3b. Subgroup analyses for Pt#7 showed that
the percentage induction of IFN-c-producing -CD8
?,
-CD4
?, and -NK cells was 31.57% (Fig. 3b, u), 11.28%
(v), and 6.8% (w), respectively ¯signiﬁes signiﬁcant induc-
tion of Th1 response and NK cell activation; similar pattern
was observed in Pt#3 (Fig. 3b, c, d, e). In case of Pt#7,
comparing with pretreatment level (Fig. 3b, k), the kinetics
of induction of IFN-c–producing-lymphocytes demon-
strated 102-fold induction after 2 HD-PegIFNa2b (l),
reached a peak (861-fold) after 4 HD-PegIFNa2b (m),
notably, 4 weeks after stopping PegIFNa2b (n) while
continuing IM showed rapid decline (22-fold). After four
weekly HD-PegIFNa2b, the treatment was switched to 18
maintenance weekly LD-PegIFNa2b (1.5 mcg/kg/week),
and we observed that four of ﬁve patients’ IFN-c-produc-
ing-lymphocytes gradually fell to non-detectable level
suggesting a PegIFNa2b dose-dependent effect. Our results
indicate that combining IM plus 4 weekly HD-PegIFNa2b
is both necessary and sufﬁcient to induce signiﬁcant gen-
eration of IFN-c–producing-lymphocytes consisting of
CD8
?, CD4
? T-lymphocytes, and NK cells in all patients
(Fig. 3a, b, b, g, i, m, o).
Post-combination-treatment residual tumor showed com-
plete remission and nearly all tumor-inﬁltrating-lympho-
cytes produce IFN-c All eight GIST patients enrolled in
the clinical trial were diagnosed with ﬁne needle aspiration
(FNA) or biopsy, so no primary GIST cells were available
to serve as targets for IFN-c-ELISPOT or
51Cr release
assay to conﬁrm ‘‘GIST-speciﬁc’’ cytotoxicity. However,
we studied the post-combination-treatment residual tumor
from Pt#4 to compared it with the same patient’s pre-
treatment biopsy sample and three post-IM-monotherapy
residual tumors as controls (Fig. 4a, controls #1–3). The
post-combination-treatment residual tumor showed patho-
logic CR, hyaline degeneration, necrosis, and abundant
tumor-inﬁltrating-lymphocytes (TILs) (Fig. 4b, m) con-
sisting of CD8
? (n) and CD4
? T-lymphocytes (p) and
CD56
? NK cells (o). Most TILs expressed CD45RO—a
memory T-lymphocyte marker (q) with negative isotype
control (r). A small fraction of TILs were positive for
granzyme B and FasL (v, w); on confocal microscopy, such
TILs mostly co-localized with CD56 (Fig. 4c, cc, gg).
Strikingly, almost all of the TILs actively produce IFN-c
(Fig. 4b, s), in sharp contrast to the totally negative IFN-c-
staining in the pretreatment GIST biopsy and all three
post-IM-monotherapy controls (Fig. 4a, c–f). Uninvolved
adjacent lymph nodes showed rare IFN-c-positive cells
(u) suggesting that combination treatment may have
induced primarily GIST-reactive TILs.
Our translational research results showed signiﬁcant
induction of IFN-c-producing -CD8
?, -CD4
?, -NK cell,
and IFN-c-producing TILs—signiﬁes induction of Th1
response and NK cell activation, thus strongly support part
one of our hypothesis.
Patients
Eight patients were enrolled (Table 1), four had stage III
and four had stage IV GIST with metastasis to liver, lungs,
and or peritoneum. Primary tumors (6–16 cm) originated
from stomach, small intestine or rectum. The GIST natural
history and response to IM treatment have been shown to
correlate with histologic features, stage, anatomical site
[24], and genotype [21, 22]. Three GISTs harbored KIT
exon 11 mutations, one had KIT exon 9 mutation, two had
wild-type (WT) KIT and PDGFRA, and two had insufﬁ-
cient material from FNA for genotyping.
Side effects
Pts#1–3 initially received HD-PegIFNa2b at 4 mcg/kg/
week, developed grade 3 neutropenia, and requiring dose
reduction to 3 mcg/kg/week. Later the protocol was
amended and the HD-PegIFNa2b was reduced to 3 mcg/
kg/week (Pts#4–8), and we observed occasional grade 1 or
grade 2 neutropenia with quick recovery. Two patients
(Pt#1 and 8) developed grade 3 skin rash requiring short-
term steroid. All patients experienced transient low-grade
fever and mild ﬂu-like symptoms as expected.
Response rate
Despite multiple poor prognostic factors, combination
treatment of IM plus PegIFNa2b achieved a response rate
(PR ? CR) of 100% by all three evaluation criteria, RE-
CIST, PET-CT scan criteria [41], and Choi criteria [42,
43], contrasting to the reported GIST IM-monotherapy
response rates of 54% [28], 52% [29, 30], and 48% [22,
30]. Pt#2 achieved PR by Choi criteria at week 8 and was
not assessable (NA) by PET-CT criteria because the tumor
1118 Cancer Immunol Immunother (2012) 61:1113–1124
123Fig. 3 Flow cytometry analysis
of IFN-c-producing-
lymphocytes. a Bar graph
demonstrating induction of IFN-
c-producing-lymphocytes
before (black bars) and after
(red bars) combination
treatment with IM plus
PegIFNa2b. b Flow cytometry
at single cell level. IFN-c-
producing-lymphocytes were
barely detectable before
treatment (a, f, h, k) and were
induced signiﬁcantly
(P\0.003) in total
lymphocytes (b, g, i, m),
subtype of CD8
? lymphocytes
(c, j, u), CD4
? lymphocytes
(d, v), and CD8
-CD4
- cells
(most likely NK) (e, w) after IM
plus 4HD-PegIFNa2b
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123was not FDG–avid or by RECIST, because the tumor was
surgically removed 6 weeks after completion of HD-Peg-
IFNa2b when tumor size had reduced by 28% and became
amenable to surgery, resulting in insufﬁcient time for
RECIST evaluation [44]. In comparison, 13% (49/382) of
genotyped GIST patients were categorized as NA by
RECIST in the S0033 trial [22]. Pt#4 had a large rectal
primary (9.3 cm; Fig. 5, top row), homozygous mutation in
KIT exon 11 [23], and high mitotic count (20/50 high
power ﬁeld), nonetheless achieved pathologic CR with
abundant IFN-c-producing TILs (Fig. 4b, s). Pt#5 (9.8 cm
primary gastric GIST and extensive liver lesions) and Pt#7
(11.4 cm primary gastric GIST) achieved radiographic
near-CR of primary GIST (Fig. 5, 2nd and 3rd row), such
that surgeries were no longer indicated—great clinical
beneﬁt. Pt#6 harboring WT GIST with extensive liver
metastasis, bilateral lung metastasis, and peritoneal
implants achieved PR by all three criteria at week 8
(Table 1; Fig. 5, 4th row); however, on day 369 of PR—
7 months after completion of PegIFNa2b—while contin-
uing IM, four existing lesions showed increased SUV.
HD-PegIFNa2b was then re-initiated with continuation of
IM 400 mg/day and resulted in a second PR (Fig. 5, last 2
rows), which lasted 430 days while off both IM and
a b c d e f
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Pt #4 biopsy before treatment and 3 control residual tumors post IM monotherapy
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gression (due to IM resistance) is unprecedented.
Progression-free survival and overall survival
After a median follow-up of 3.6 years (3.2–4.3 years), the
OS is 100% with PS = ECOG 0 for all seven evaluable
patients. Pt#1 had unsuccessful genotyping and was
grouped with KIT exon 11—the most favorable group—for
the evaluation. Pt#7 died at age 85 of unrelated illness
while in remission with a radiographic near-CR (Table 1;
Fig. 5, 3rd row). The PFS of Pt#6 and the continuing PR/
CR of Pts#1, 2, 4, 5, and 8—a total of 6 out of 7 evalu-
able patients—exceed not only the genotype-speciﬁc
median PFS [22] but also the upper limit of the 95%
conﬁdence level of the genotype-speciﬁc PFS of S0033
Fig. 5 PET-CT and CT scans.
Top three rows show that the
combination treatment resulted
in swift radiographic CR or
near-CR of large primary GIST
of Pts#4, 5, and 7 (9.3, 9.8, and
11.4 cm). Pt#6 showed mixed
PR and CR (fourth row). Last
two rows illustrate the second
PR (after emergence of IM
resistance) induced by re-
initiation of PegIFNa2b
1122 Cancer Immunol Immunother (2012) 61:1113–1124
123IM-monotherapy trial (Table 1, last column; S0033 Study
data are in brackets) [Personal communication with Dr.
Michael C. Heinrich, PI of IM-monotherapy phase III
S0033 Study]. Pt#3 harbored aggressive GIST with
extensive liver metastasis and achieved PR at week 8 by all
three criteria, but three out of the numerous liver lesions
showed evidence of increased SUV on PET-CT scan
without new lesions on day 765, and the genotype-speciﬁc
PFS was slightly longer than that of S003 IM-monotherapy
trial [22].
Taken together, combination treatment with IM plus
PegIFNa2b was well tolerated, safe, demonstrated a 100%
response rate (PR ? CR), 100% OS rate, and substantially
prolonged continuing PR/CR (5 patients) and PFS (2
patients) after a median follow-up of 3.6 years (3.2–
4.3 years), and strongly supports part two and three of our
hypothesis.
Discussion
In CML, combining two active agents, peginterferon-alfa-
2a (Pegasys
) and IM, demonstrated tolerability and
improved efﬁcacy over IM-monotherapy [45], but the
immunological implications of IFN-a was not addressed.
Our GIST study of adding PegIFNa2b (immunotherapy) to
the current standard IM (targeted therapy) demonstrated
signiﬁcant induction of innate immunity and Th1 response
and highly promising clinical outcome comparing to IM-
monotherapy albeit small group study, and strongly sup-
ported our hypothesis. Although IM has off-target effect of
activating innate [32, 33] and potentiating adaptive
immunity [34, 35], the signiﬁcant induction of IFN-c-pro-
ducing-lymphocytes (Fig. 3a) in this study is mainly
attributed to PegIFNa2b rather than IM alone because
stopping HD-PegIFNa2b (Fig. 3b, n) or switching to
maintenance LD-PegIFNa2b while continuing IM resulted
in a sharp decline of IFN-c-producing-lymphocytes to
barely detectable level. This new concept/strategy of
combining immunotherapy with effective non-marrow-
suppressive treatments might be beneﬁcial to other cancer
types as well. Combining IFN-a or peginterferon a with
radiation, hormone/hormone antagonist, small molecule
targeted therapies, or monoclonal antibodies in radiosen-
sitive tumors, prostate, breast, pancreatic, melanoma,
hepatocellular, colorectal, and sarcoma may help delay/
prevent relapse and warrant further investigations.
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